An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis ...
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Followin ...